Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581898 | 0.81 | CCR5 (0.56) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3874242 | 0.78 | CCR5 (0.71) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL5078759 | 0.76 | CCR5 (0.51) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL5078754 | 0.72 | CCR5 (0.54) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL30529985 | 0.72 | CCR5 (0.90) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3874247 | 0.72 | CCR5 (0.90) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL4939107 | 0.69 | CCR5 (0.60) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3873705 | 0.69 | CCR5 (0.60) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL12611791 | 0.68 | CCR5 (0.51) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL15169901 | 0.68 | CCR5 (0.78) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576097-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080132537-A1 | TROPANE DERIVATIVES USEFUL IN THERAPY | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132537-A1 | TROPANE DERIVATIVES USEFUL IN THERAPY | ADRB3, ADRB2, ADRA2C | CCR5 407/4885KCNH2 1335/4885CYP3A4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.